Rhumbline Advisers lifted its stake in shares of Tocagen Inc (NASDAQ:TOCA) by 9.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,491 shares of the company’s stock after purchasing an additional 2,188 shares during the quarter. Rhumbline Advisers’ holdings in Tocagen were worth $277,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. raised its stake in shares of Tocagen by 9.0% during the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock worth $94,000 after purchasing an additional 949 shares during the last quarter. Bank of America Corp DE raised its position in Tocagen by 28.6% in the fourth quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock worth $120,000 after acquiring an additional 3,240 shares in the last quarter. Bank of New York Mellon Corp raised its position in Tocagen by 7.7% in the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock worth $468,000 after acquiring an additional 4,093 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Tocagen by 72,350.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock worth $47,000 after acquiring an additional 4,341 shares in the last quarter. Finally, Stifel Financial Corp raised its position in Tocagen by 34.0% in the fourth quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock worth $215,000 after acquiring an additional 6,698 shares in the last quarter. Institutional investors and hedge funds own 35.09% of the company’s stock.
NASDAQ:TOCA opened at $6.22 on Friday. The firm has a market capitalization of $141.26 million, a price-to-earnings ratio of -2.55 and a beta of 3.79. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.05 and a quick ratio of 5.05. Tocagen Inc has a 1 year low of $4.13 and a 1 year high of $15.80.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $2.01 million. Tocagen had a negative return on equity of 108.08% and a negative net margin of 294.74%. As a group, sell-side analysts anticipate that Tocagen Inc will post -2.94 EPS for the current year.
Several research analysts have issued reports on the company. Zacks Investment Research cut Tocagen from a “buy” rating to a “hold” rating in a research report on Tuesday. Citigroup assumed coverage on Tocagen in a research report on Thursday, May 30th. They issued a “buy” rating for the company. Leerink Swann set a $5.00 price objective on Tocagen and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. Chardan Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Tocagen in a research report on Wednesday, May 22nd. Finally, ValuEngine cut Tocagen from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $16.30.
In other news, Director Faheem Hasnain bought 43,000 shares of the stock in a transaction on Thursday, May 30th. The shares were bought at an average price of $4.66 per share, with a total value of $200,380.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 53,000 shares of company stock worth $244,880 in the last three months. 10.90% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Rhumbline Advisers Has $277,000 Stake in Tocagen Inc (NASDAQ:TOCA)” was posted by Modern Readers and is the sole property of of Modern Readers. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.modernreaders.com/news/2019/06/14/rhumbline-advisers-has-277000-stake-in-tocagen-inc-nasdaqtoca.html.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: Bear Market
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.